Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-5190457. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-5190457 SCHEMBL29766846 | 1.00 | GHSR (1.00) | GHSRHTR2BKCNH2CHRM2 | |
| Pf-5190457 SCHEMBL2435827 | 1.00 | GHSR (1.00) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2443560 | 0.89 | GHSR (0.80) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2448471 | 0.89 | GHSR (0.80) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2441171 | 0.88 | GHSR (0.79) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2435069 | 0.88 | GHSR (1.00) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2434907 | 0.88 | GHSR (1.00) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2445569 | 0.87 | GHSR (0.78) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2433844 | 0.87 | GHSR (0.78) | GHSRHTR2BKCNH2CHRM2 | |
| SCHEMBL2436992 | 0.87 | GHSR (0.88) | GHSRHTR2BKCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854856-B1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER (US) | 2019-01-23 | — | — | EP | claimed |
| US-9370516-B2 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders | PFIZER INC. (US) | 2016-06-21 | — | — | US | claimed |
| EP-2547679-B1 | 2,3 DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER (US) | 2015-11-04 | — | — | EP | claimed |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER INC. (US) | 2015-04-30 | — | — | US | claimed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | claimed |
| US-8609680-B2 | 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | PFIZER INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | claimed |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-2854856-B1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2854856-B1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8609680-B2 | 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | PFIZER INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2011114271-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | FABP7, PYGB, ATP6V1B2 | GHSR 47/4885HTR2B 648/4885KCNH2 3050/4885 |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | GIPR, GHSR, HCRTR2 | GHSR 2/4885HTR2B 103/4885KCNH2 1416/4885 |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | GIPR, GLP1R, GHSR | GHSR 3/4885HTR2B 355/4885KCNH2 1041/4885 |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | CRH, PYGB, CHAT | GHSR 10/4885HTR2B 160/4885KCNH2 4541/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | GHSR 2/4885HTR2B 362/4885KCNH2 2931/4885 |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | GIPR, GLP1R, GHSR | GHSR 3/4885HTR2B 366/4885KCNH2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.